HIV Diagnostics Testing Market is Segmented By Product(Consumables, Assays and Kits & Reagents, Other Consumables, Instruments, Software & Services), By Test Type(Antibody Tests, Viral Load Tests, CD4 Tests, Other), By Application(Diagnostic Laboratories, Hospitals, Other), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.
HIV Diagnostics Testing Market is Predicted to reach at a CAGR of 6.3% during the forecast period (2022-2029).
HIV diagnostics are used to detect the human immunodeficiency virus in saliva, serum, or urine. HIV diagnostics aids in detecting antibodies, RNA, and antigens.
HIV Diagnostics Testing Market
|
Metrics |
Details |
|
Market CAGR |
6.3% |
|
Segments Covered |
By Product, By Test Type, By Application, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
HIV Diagnostics Testing Market Dynamics
The factors influencing the global HIV diagnostics market are the increasing demand for HIV diagnostics, and the growing prevalence of HIV is expected to drive the market growth.
The increasing demand for HIV diagnostics is expected to drive market growth in the forecast period
The increasing awareness about HIV is expected to drive the demand for HIV diagnostics testing. For instance, India's AIDS Control Program is widely regarded as a success story worldwide. The National AIDS Control Programme (NACP) is being implemented as a comprehensive programme for HIV/AIDS prevention and control in India. Over time, the emphasis has shifted from raising awareness to behaviour change, from a national response to a more decentralized response, and increased involvement of NGOs and PLHIV networks to increased involvement of PLHIV networks.
Coordinated action is urgently needed in low- and middle-income countries (LMICs) with the highest HIV burden to ensure that the ambitious 90-90-90 HIV treatment targets set by the Joint United Nations Programme on HIV and AIDS are met. The targets anticipate that by 2020, 90 percent of people living with HIV will be aware of their status, 90 percent of those diagnosed with HIV will begin antiretroviral therapy (ART), and 90 percent of those receiving ART will have long-term viral suppression. Furthermore, the CDC recommends that everyone between 13 and 64 in the United States get tested for HIV at least once.
The drawbacks associated with HIV diagnostics testing is expected to hamper the market growth
The window period is one of the most serious issues with HIV testing (the time between a person being infected with HIV and their body producing enough antibodies for a test to detect). A negative test result could indicate that someone was recently infected with HIV. A positive test result can sometimes be a 'false positive,' leading the person to believe they have HIV when they do not. A negative test result could be a 'false negative,' implying that the person believes they do not have HIV when they do. The cost of testing is also one major reason expected to hamper the market. For instance, HIV testing is extremely expensive. It puts a strain on healthcare budgets in areas where resources are scarce. Except for blood transfusion services, where testing is required, the benefits of testing must be carefully considered. In addition, despite having enough trained counselors, the hospital lacks funds to cover the cost of testing kits, and the supply is unreliable.
COVID-19 Impact Analysis
Over the last year, the occurrence of the COVID-19 pandemic had a significant negative impact on healthcare systems. Healthcare providers were forced to focus primarily on COVID-19 patients, ignoring equally important diseases, both acute and chronic, in many cases. As a result, HIV screening and diagnostic strategies may have been significantly hampered. During the pandemic, there was a significant reduction in HIV diagnoses. People living with HIV during the pandemic, on the other hand, were older and diagnosed at an earlier stage of disease (based on CD4+ T cell count) than those diagnosed the previous year. Furthermore, there was a significant decrease in new HIV diagnoses among men who have sex with men, most likely due to the government's social distancing and restrictions. Even if the number of late presentations in 2020 is lower than in 2019, it remains an issue.
HIV Diagnostics Testing Market Segment Analysis
By test type, the antibody tests segment is expected to dominate the market
HIV antibodies are detected in blood or saliva by the Antibody test. When bacteria or viruses enter the body, the immune system produces antibodies. After 3–12 weeks of infection, an HIV antibody test can determine if the person is positive. This can take several weeks or longer for the immune system to produce antibodies against HIV. With the kits, the patient can perform an HIV antibody test in the privacy of their own home. The majority of rapid and self-tests are antibody tests. In general, antibody tests using blood from a vein can detect HIV sooner than tests using blood from a finger prick or oral fluid.
Furthermore, on September 30th, 2020, Roche launched the Elecsys HIV Duo immunoassay in the United States. This test can detect an acute HIV infection earlier than current methods by measuring the HIV p24 antigen (the virus) and anti-HIV antibodies.
HIV Diagnostics Testing Market Geographical Analysis
North America region is expected to hold the largest market share in the global HIV diagnostics testing market
The presence of key players, the high prevalence of HIV/AIDS in the region, and established healthcare infrastructure are some of the key factors expected to drive the market in this region. According to the most recent Centers for Disease Control and Prevention estimates, 37,832 people in the United States were diagnosed with HIV in 2018. Furthermore, advantageous government initiatives and an increase in research collaborations. The CDC in the United States recommends routine HIV screening in healthcare settings for all adults aged 13 to 64, with at least annual repeat screening for those at higher risk.
HIV Diagnostics Testing Market Competitive Landscape
The global HIV diagnostics testing market is highly competitive with mergers, collaborations, and product launches. Some of the key players in the market are Siemens Healthineers, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Danaher Corporation, Thermo-Fisher Scientific Inc., Merck KGaA, Becton, Dickinson & Company, Hologic Inc., JOYSBIO (Tianjin) Biotechnology Co., Ltd., and Bio-Rad Laboratories
Frequently Asked Questions
What is the Projected CAGR value of the HIV Diagnostics Testing Market?
HIV Diagnostics Testing Market is expected to grow at a CAGR of 6.3% during the forecasting period 2022-2029.
Which region controlled the global market during 2022-2029?
North America region Controls the HIV Diagnostics Testing Market during 2022-2029
Which is the fastest growing region in the HIV Diagnostics Testing Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period
